2023 | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study | Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; Crow, Lauren; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Santiago-Walker, Ademi; Triantos, Spyros; Sweiti, Hussein; Loriot, Yohann; CHIH-HUNG HSU | The Lancet. Oncology | 22 | | |
2022 | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors | Chan, Stephen L; Schuler, Martin; Kang, Yoon-Koo; Yen, Chia-Jui; Edeline, Julien; Choo, Su Pin; CHIA-CHI LIN ; Okusaka, Takuji; Weiss, Karl-Heinz; Macarulla, Teresa; Cattan, Stéphane; Blanc, Jean-Frederic; Lee, Kyung-Hun; Maur, Michela; Pant, Shubham; Kudo, Masatoshi; Assenat, Eric; Zhu, Andrew X; Yau, Thomas; Lim, Ho Yeong; Bruix, Jordi; Geier, Andreas; Guillén-Ponce, Carmen; Fasolo, Angelica; Finn, Richard S; Fan, Jia; Vogel, Arndt; Qin, Shukui; Riester, Markus; Katsanou, Vasiliki; Chaudhari, Monica; Kakizume, Tomoyuki; Gu, Yi; Porta, Diana Graus; Myers, Andrea; Delord, Jean-Pierre | Journal of experimental & clinical cancer research : CR | 20 | | |